A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors

Summary

This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid tumors. This study consists of the tolerability confirmation part to determine the recommended dose for Japanese participants by evaluating the DLTs and the expansion part to evaluate the safety and pharmacokinetics and to explore the efficacy.

Timeline

Start

2024-05-07

Primary completion

2028-02-29

Completion

2028-02-29

Drugs

Indications

No indication recorded.